ArticleTranslational lung cancer research2025
Immunohistochemical analysis of p53 and LKB1 as predictive biomarkers of immune checkpoint inhibitor response in non-small cell lung cancer.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) are a mainstay in the treatment of non-small cell lung cancer (NSCLC). Although accurate predictive biomarkers are required for treatment selection-considering the risk of serious immune-related adverse events-such predictors remain limited. In this study, we aimed to evaluate the association between the expression of p53, LKB1, and NRF2 proteins and ICI efficacy. Methods: This retrospective analysis included patients with NSCLC who received first-line ICI-based therapy or epidermal growth factor receptor-tyrosine kinase inhibitors between 2017 and 2025 at our institute. Immunohistochemistry was performed on diagnostic samples to assess p53, LKB1, and NRF2 expression and tumor-infiltrating lymphocytes (TILs). Additionally, the associations between biomarker expression and clinical outcomes were examined. Results: Among the 43 evaluable cases in the ICI group, aberrant p53 expression was observed in 46.5%, LKB1 loss in 13.9%, and nuclear-dominant NRF2 expression in 34.9% of cases. Aberrant p53 expression was associated with increased TILs and improved progression-free survival (PFS), while the loss of LKB1 was correlated with an immunosuppressive microenvironment and shorter PFS. Nuclear-dominant NRF2 expression was associated with poorer overall survival. Conclusions: The immunohistochemical profiles of p53 and LKB1 are associated with distinct immune microenvironment features. These markers may serve as surrogate predictors of ICI efficacy in patients with NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.